期刊
VACCINE
卷 28, 期 50, 页码 7939-7946出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.09.076
关键词
West Nile Virus; Formalin-inactivated vaccine; Vaccine Efficacy Test; Cross-neutralization test
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)
- MEXT, the Ministry of Health [07459098, 16406029, 18406017, H-17-Shinko-2, B:1440619]
- St. Luke's Medical Center [01-017, 01-018]
- Grants-in-Aid for Scientific Research [18406017, 16406029] Funding Source: KAKEN
A formalin-inactivated West Nile Virus (WNV) vaccine (WN-VAX) derived from the WNV-NY99 strain was tested for its safety, efficacy, dilution limit for complete protection, and cross-neutralization. Safety tests performed with experimental animals, bacteria, or cultured cell lines showed no evidence of short-or long-term adverse effects. WN-VAX also protected 100% of 4-week-old mice against a lethal challenge from the WNV-NY99 strain after two doses of intraperitoneal inoculation even when the vaccine was diluted to 3.2 ng/dose. Moreover, very limited cross-neutralization activity against Japanese encephalitis virus, Dengue virus, Murray Valley encephalitis virus, Yellow fever virus or St. Louis encephalitis virus was observed. Therefore, the WN-VAX satisfies the requirements for human trials planned to be done in Japan. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据